AptamiR is developing breakthrough therapies based on the research of Craig Mello and Andrew Fire who won the 2006 Nobel Prize for Physiology or Medicine for the discovery of RNA interference.
Human obesity, Type 2 Diabetes Mellitus (T2DM) and Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) are growing worldwide pandemics caused by sedentary lifestyle and excessive consumption of energy-dense foods rich in saturated lipids and carbohydrates.
Current medical treatments of obesity:
- have poor benefit-to-risk profiles
- fail to reach their long-term goals and
- do not meet patients’ expectations
There is currently no approved drug for the treatment of MAFLD.
Obesity and Metabolic Dysfunction Associated Fatty Liver Disease are in need of safe, effective and convenient therapies
AptamiR’s goal is to develop new therapies that target fat accumulation, inflammation, and necrosis to cure related cardiometabolic disorders (dyslipidemia, diabetes and metabolic dysfunction-associated fatty liver disease (MAFLD)), without altering brain functions, but improving patients quality of life.
AptamiR’s distinctive model of virtual, outsourced, and cost-effective drug research and development has resulted in the achievement of several proof of concept milestones within a few years in operations:
Our strategy is to develop Oligonucleotide Therapeutics (ONTs) which transform fat-storing cells (white adipocytes) into fat-burning cells (“browning effect”).
Our End goal is to help patients live longer and healthier lives while reducing healthcare costs
AptamiR Therapeutics, Inc., a US modular biotechnology company founded in 2012, is focused on developing a revolutionary treatment for human obesity and related cardiometabolic disorders. Based on an innovative strategy targeting subcutaneous fat cells rather than the central nervous system or the intestinal absorption of food, AptamiR is developing microRNA-targeted therapeutics that enhance lipid oxidation and thermogenesis, turning fat-storing white adipocytes into fat-burning adipocytes (so called brown-like, brite or beige).
MicroRNA analogs are attractive drug candidates for complex diseases like obesity, diabetes and MAFLD, as they simultaneously modulate the expression of gene networks (One Drug-Multiple Targets concept).
AptamiR is also developing original drug delivery systems that can specifically supply microRNA analogs to adipose tissues or other particular organs and tissues.